Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.	Serial No.
27611/36928	09/995,263
Applicant	
Onyuksel, H. *et al.*	
Filing Date	**Group**
November 27, 2001	1615

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	4,529,561	07/16/85	Hunt, C.A. *et al.*	264	4.3	
	A2	4,920,016	04/24/90	Allen, T.M. *et al.*	424	450	
	A3	5,013,556	05/07/91	Woodle, M.C. *et al.*	424	450	
	A3	5,225,212	07/06/93	Martin, F.J. *et al.*	424	450	
	A5	5,230,882	07/27/93	Unger, E.C.	424	9	
	A6	5,374,548	12/20/94	Caras, I.W.	424	450	
	A7	5,484,894	01/16/96	Woiszwillo, J.E.	530	410	
	A6	5,514,670	05/07/96	Friedman, D. *et al.*	514	2	
	A9	5,534,241	07/09/96	Torchilin, V.P. *et al.*	424	9.321	
	A10	5,542,935	08/06/96	Unger, E.C. *et al.*	604	450	
	A11	5,543,390	08/06/96	Yatvin, M.B. *et al.*	514	2	
	A12	5,545,569	08/13/96	Grainger, D.J. *et al.*	436	518	
	A13	5,552,156	09/03/96	Burke, T.G.	424	450	
	A14	5,567,410	10/22/96	Torchilin, V.P. *et al.*	424	9.4	
	A15	5,573,934	11/12/96	Hubbell, J.A. *et al.*	435	177	
	A16	5,578,709	11/26/96	Woiszwillo, J.E.	530	410	
	A17	5,580,575	12/03/96	Unger, E.C. *et al.*	424	450	
	A18	5,580,853	12/03/96	Sytkowski, A.J.	514	8	

EXAMINER	DATE CONSIDERED
	5/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) | U.S. Department of Commerce, Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.	Serial No.
27611/36928	09/996,263
Applicant	
Onyuksel, H. *et al.*	
Filing Date	**Group**
November 27, 2001	1615

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A19	5,585,112	12/17/96	Unger, E.C. *et al.*	424	450	
	A20	5,587,149	12/24/96	Punto, L. *et al.*	424	59	
	A21	5,589,453	12/31/96	Greve, J.M. *et al.*	514	8	
	A22	5,595,722	01/21/97	Grainger, D.J. *et al.*	424	9.2	
	A23	5,612,027	03/18/97	Galin, M.A. *et al.*	424	78.04	
	A24	5,633,226	05/27/97	Owen, A.J. *et al.*	514	2	
	A25	5,635,187	06/03/97	Bathurst, I.C. *et al.*	424	195.1	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	0082311	05/22/82	JP	—	—	*ABSTRACT ONLY*	
	B2	WO 93/20802	10/28/93	WIPO	—	—		
	B3	WO 95/27496	10/19/95	WIPO	—	—		
	B4	WO 97/35560	10/02/97	WIPO	—	—		
	B5	WO 97/35561	10/02/97	WIPO	—	—		

EXAMINER	DATE CONSIDERED
Kam	5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27611/36928	Serial No. 09/995,263
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Onyuksel, H. *et al.*	
		Filing Date November 27, 2001	Group 1615

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C1	Alessandrini, F. *et al.*, "Vasoactive Intestinal Peptide Enhances Lung Preservation," *Transplantation, 56(4)*:964-973 (October, 1993).
	C2	Alexandridis, P. *et al.*, "Temperature Effects of Structural Properties of Pluronic P104 and F108 PEO-PPO-PEO Block Copolymer Solutions," *Langmuir, 11*:1468-1476 (1995).
	C3	Alkan-Onyuksel, H. *et al.*, "A Mixed Micellar Formulation Suitable for the Parenteral Administration of Taxol," *Pharmaceutical Research, 11(2)*:206-212 (1994).
	C4	Alkan-Onyuksel, H. *et al.*, "Development of Inherently Echogenic Liposomes as an Ultrasonic Contrast Agent," *Journal of Pharmaceutical Sciences, 85(5)*:486-490 (May, 1996).
	C5	Allen, T.M. *et al.*, "Large Unilamellar Liposomes with Low Uptake into the Reticuloendothelial System," *Federation European Biochemical Societies, 223(1)*:42-46 (October, 1987)
	C6	Allen, T.M. *et al.*, "Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo," *Biochimica et Biophysica Acta, 1066*:29-36 (1991).
	C4	Almgren, M. *et al.*, "Self-aggregation and phase behavior of poly(ethylene oxide)-poly(propylene oxide)-poly(ehtylene oxide) block copolymers in aqueous solution," *Colloid Polym Sci., 273*:2-15 (1995).
	C8	Artwohl, J.F. *et al.*, "Initial Characterization of Hamsters with Spontaneous Hypertension," *FASEB J., 10*:A628 (1996).
	C9	Avidor, R. *et al.*, "VIP-mRNA is increased in hypertensive rats," *Brain Research, 503*:304-307 (1989).
	C10	Bangham, A.D. *et al.*, "Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids," *J. Mol. Biol., 13*:238-252 (1965).

EXAMINER	DATE CONSIDERED 5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27611/36928	Serial No. 09/995,263
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Onyuksel, H. *et al.*	
		Filing Date November 27, 2001	Group 1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C11	Beaumier, P.L. *et al.*, "Effect of Liposome Dose on the Elimination of Small Unilamellar Sphingomyelin/Cholesterol Vesicles from the Circulation," *Research Communications in Chemical Pathology and Pharmacology, 39(2)*:277-289 (February, 1983).
	C12	Beaumier, P.L. *et al.*, "Effects of Liposome Size on the Degradation of Bovine Brain Sphingomyelin/Cholesterol Liposomes in the Mouse Liver," *Biochimica et Biophysica Acta, 731*:23-30 (1983).
	C13	Bedu-Addo, F.K. *et al.*, "Interaction of Polyethyleneglycol-Phospholipid Conjugates with Cholesterol-Phosphatidylcholine Mixtures: Sterically Stabilized Liposome Formulations," *Pharmaceutical Research, 13(5)*:718-724 (1996)
	C14	Berisha, H. *et al.*, "Vasoactive intestinal peptide prevents lung injury due to xanthine oxidase," *Am. J. Physiol., 259*:L151-L155 (1990).
	C15	Bodanszky, M. *et al.*, "A Preferred Conformation in the Vasoactive Intestinal Peptide (VIP). Molecular Architecture of Gastrointestinal Hormones," *Bioorganic Chemistry, 3*:133-140 (1974).
	C16	Bolin, D.R. *et al.*, "Design and Development of a Vasoactive Intestinal Peptide Analog as a Novel Therapeutic for Bronchial Asthma," *Biopolymers, (Peptide Science) 37*:57-66 (1995).
	C14	Carey, M.C. *et al.*, "Micelle Formation by Bile Salts," *Arch Inter. Med., 130*:506-527 (October, 1972).
	C15	Chiba, K. *et al.*, "Interaction Between Lipids and Bovine Brain Calmodulin: Lysophosphatidylcholine-Induced Conformation Change," *Life Science, 47*:953-960 (1990).
	C19	Damrongchai, N. *et al.*, "Calcium Responsive Two-Dimensional Molecular Assembling of Lipid-Conjugated Calmodulin," *Bioconjugate Chem., 6*:261-268 (1995).

EXAMINER	DATE CONSIDERED 5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27611/36928	Serial No. 09/995,263
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Onyuksel, H. *et al.*	
		Filing Date November 27, 2001	Group 1615

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C20	DeGrado, W.F. *et al.*, "Induction of Peptide Conformation at Apolar/Water Interfaces. 1. A Study with Model Peptides of Defined Hydrophobic Periodicity," *J. Am. Chem. Soc., 107*:7684-7689 (1985).
	C21	Demos, S.M. *et al.*, "In Vitro Targeting of Antibody-Conjugated Echogenic Liposomes for Site-Specific Ultrasonic Image Enhancement," *Journal of Pharmaceutical Sciences, 86(2)*:167-171 (February, 1997).
	C22	Fournier, A. *et al.*, "Synthesis, Conformational Studies and Biological Activities of VIP and Related Fragments," *Peptides 5*:169-177 (1984).
	C23	Frase, L.L. *et al.*, "Cardiovascular Effects of Vasoactive Intestinal Peptide in Healthy Subjects," *Am. J. Cardio., 60*:1356-1361 (1987).
	C24	Fry, *D.C. et al.*, "Solution Structure of an Analogue of Vasoactive Intestinal Peptide As Determined by Two-Dimensional NMR and Circular Dichroism Spectroscopies and Constrained Molecular Dynamics," *Biochemistry, 28*:2399-2409 (1989).
	C25	Gabizon, A. *et al.*, "Liposome Formulations with Prolonged Circulation Time in Blood and Enhanced Uptake by Tumors," *Proc. Natl. Acad. Sci. (USA), 85*:6949-6953 (September, 1988).
	C26	Gao, X. *et al.*, "Loop diuretics attenuate bradykinin-induced increase in clearance of macromolecules in the oral mucosa," *J. Appl. Physiol., 80(3)*:818-823 (1996).
	C27	Gao, X. *et al.*, "Vasoactive Intestinal Peptide Encapsulated in Liposomes: Effects on Systemic Arterial Blood Pressure," *Life Sciences, 54(15)*: PL247-PL252 (1994).
	C28	Gozes, I. *et al.*, "VIP: Molecular Biology and Neurobiological Function," *Molecular Neurobiology, 3*:201-236 (1989).
	C29	Gozes, I. *et al.*, "Stearyl-Norleucine-Vasoactive Intestinal Peptide (VIP): A Novel VIP Analog for Noninvasive Impotence Treatment," *Endorinology, 134(5)*:2121-2125 (1994).

EXAMINER	DATE CONSIDERED 5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27611/36928	Serial No. 09/995,263
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Onyuksel, H. *et al.*	
		Filing Date November 27, 2001	Group 1615

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C30	Gozes, I. *et al.*, "Superactive Lipophilic Peptides Discriminate Multiple Vasoactive Intestinal Peptide Receptors," *J. Pharmacology Experimental Therapeutics, 273(1)*:161-167 (1995).
	C31	Gregoriadias, G. *et al.*, "Fate of Protein-Containing Liposomes Injected into Rats: An Approach to the Treatment of Storage Diseases," *Eur. J. Biochem. 24*:485-491 (1972).
	C32	Gregoriadis, G. *et al.*, "Liposomes in Drug Delivery: Clinical, Diagnostic and Ophthalmic Potential," *Drugs, 45(1)*:15-28 (1993).
	C33	Haghjoo, K. *et al.*, "Solution Structure of Vasoactive Intestinal Polypeptide (11-28)-NH_2, a Fragment with Analgesic Properties," *Peptide Research, 9(6)*:327-331 (1996).
	C34	Hamed, M.M. *et al.*, "Behavior of Amphipathic Helices on Analysis via Matrix Methods, with Application to Glucagon, Secretin, and Vasoactive Intestinal Peptide," *Biopolymers, 22*:1003-1021 (1983).
	C35	Hirata, Y. *et al.*, "Functional Receptors For Vasoactive Intestinal Peptide In Cultured Vascular Smooth Muscle Cells From Rat Aorta," *Biochemical Biophysical Research Communications, 132(3)*:1079-1087 (November, 1985).
	C36	Hjelm, R.P. Jr. *et al.*, "Organization of Phosphatidylcholine and Bile Salt in Rodlike Mixed Micelles," *J. Phys. Chem., 96(21)*:8653-8661 (1992).
	C37	Hökfelt, T., "Neuropeptide in Perspective: The Last Ten Years," *Neuron, 7*:867-879 (1991).
	C38	Houbre, D. *et al.*, "The Interactions of the Brain-specific Calmodulin-binding Protein Kinase C Substrate, Neuromodulin (GAP 43), with Membrane Phospholipids," *Journal Biological Chemistry, 266(11)*:7121-7131 (April, 1991).
	C39	Hristova, K. *et al.*, "Effect of Bilayer Composition on the Phase Behavior of Liposomal Suspensions Containing Poly(ethylene glycol)- Lipids," *Macromolecules, 28(23)*:7793-7799 (1995).

EXAMINER	DATE CONSIDERED 5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27611/36928	Serial No. 09/995,263
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Onyuksel, H. *et al.*	
		Filing Date November 27, 2001	Group 1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C40	Hristova, K. *et al.*, "Phase Behavior of a Lipid/Polymer-Lipid Mixture in Aqueous Medium," *Macromolecules, 28*:991-1002 (1995).
	C41	Hwang, K.J., "Liposome Pharmacokinetics," in *Liposomes from Biophysics to Therapeutics*, Ostro, M.J. (Ed.), Marcel Dekker, Inc., New York, pp. 109-156 (1987).
	C42	Kaiser, E.T. *et al.*, "Peptides with Affinity for Membranes," *Ann. Rev. Biophys. Biophysical Chem., 16*:561-581 (1987).
	C43	Kates, M., in *Laboratory Techniques in Biochemistry and Molecular Biology: Techniques in Lipidology Isolation, Analysis and Identification of Lipids*, Work, T.S. *et al.*, (Eds.) North-Holland/American Elsevier , New York, New York, USA, pp. 354-356 (1972).
	C44	Kedar, E. *et al.*, "Delivery of Cytokines by Liposomes. I. Preparation and Characterization of Interleukin-2 Encapsulated in Long-Circulating Sterically Stabilized Liposomes," *Journal of Immunotherapy, 16*:47-59 (1994).
	C45	Kenworthy, A.K. *et al.*, "Structure and Phase Behavior of Lipid Suspensions Containing Phospholipids with Covalently Attached Poly(ethylene glycol)," *Biophysical Journal, 68*:1903-1920 (May, 1995).
	C46	Kirby, C. *et al.*, "Dehydration-Rehydration Vesicles: A Simple Method for High Yield Drug Entrapment in Liposomes," *Biotechnology*, pp. 979-984 (November 1984).
	C47	Kirby, C. *et al.*, "Effect of the Cholesterol Content of Small Unilamellar Liposomes on their Stability *in vivo* and *in vitro*," *Biochem. J., 186*:591-598 (1980).
	C48	Klibanov, A.L. *et al.*, "Activity of amphipathic poly(ethylene glycol) 5000 tp prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target," *Biochimica Biophysica Acta, 1062*:142-148 (1991).
	C49	Klibanov, A.L. *et al.*, "Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes," *FEBS Lett., 268(1)*:235-237 (July, 1990).

EXAMINER	DATE CONSIDERED 5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27611/36928	Serial No. 09/995,263
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Onyuksel, H. *et al.*	
		Filing Date November 27, 2001	Group 1615

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C50	Krejs, G.J., "Effect of Vasoactive Intestinal Peptide in Man," *Am. N.Y. Acad. Sci., 527*:501-507 (1988).
	C51	Lasic, D. *et al.*, *Stealth Liposomes*, Lasic, D. *et al.*, (Eds.), CRC Press, Inc., Boca Raton, FL, pp. 1-289 (1995).
	C52	Litzinger, D.C. *et al.*, "Effect of Liposome Size on the Circulation Time and Intraorgan Distribution of Amphipathic Poly(ethylene glycol)-Containing Liposomes," *Biochimica et Biophysica Acta, 1190*:99-107 (1994).
	C53	Liu, D. *et al.*, "Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM_1-containing liposomes," *Biochimica et Biophysica Acta, 1104*:95-101 (1992).
	C54	Lutz, E.M. *et al.*, "The VIP_2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide," *FEBS Lett, 334(1)*:3-8 (November, 1993).
	C55	MacDonald, R.C. *et al.*, "Small-Volume Extrusion Apparatus for Preparation of Large, Unilamellar Vesicles," *Biochimica et Biophysica Acta, 1061*:297-303 (1991).
	C56	Malhotra, R.K. *et al.*, "Vasoactive Intestinal Polypeptide and Muscarine Mobilize Intracellular Ca^{2+} through Breakdown of Phosphoinositides to Induce Catecholamine Secretion," *Journal of Biological Chemistry, 263(5)*:2123-2126 (1988).
	C54	Maruyama, K. *et al.*, "Effect of Molecular Weight in Amphipathic Polyehtyleneglycol on Prolonging the Circulation Time of Large Unilamellar Liposomes," *Chem. Pharm. Bull., 39(6)*:1620-1622 (1991).
	C58	Mayhan, W.G. *et al.*, "Acetylcholine Induces Vasoconstriction in the Microcirculation of Cardiomyopathetic Hamsters: Reversal by L-Arginine," *Biochemical and Biophysical Research Communications, 184(3)*:1372-1377 (May, 1992).

EXAMINER	DATE CONSIDERED 5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27611/36928	Serial No. 09/995,263
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Onyuksel, H. *et al.*	
		Filing Date November 27, 2001	Group 1615

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C59	Mayhan, W.G. *et al.*, "The Effect of Altering the External Calcium Concentration and a Calcium Channel Blocker, Verapamil, on Microvascular Leaky Sites and Dextran Clearance in the Hamster Cheek Pouch," *Microvascular Research, 28*:159-179 (1984).
	C60	Morice, A. *et al.*, "Vasoactive Intestinal Peptide Causes Bronchodilatation and Protects Against Histamine-Induced Bronchoconstriction in Asthmatic Subjects," *Lancet, 262(8361)*:1225-1227 (November, 1983).
	C61	Muller, J. *et al.*, "VIP as a Cell-Growth and Differentiation Neuromodulator Role in Neurodevelopment," *Molecular Neurobiology, 10*:115-134 (1995).
	C62	Muranushi, N. *et al.*, "Effect Of Fatty Acids And Monoglycerides On Permeability Of Lipid Bilayer," *Chemistry and Physics of Lipids, 28*:269-279 (1981).
	C63	Musso, G.F. *et al.*, "Development of Helix-Based Vasoactive Intestinal Peptide Analogues: Identification of Residues Required for Receptor Interaction," *Biochemistry, 27*:8174-8181 (1988).
	C64	Nivaggioli, T. *et al.*, "Fluorescence Probe Studies of Pluronic Copolymer Solutions as a Function of Temperature," *Langmuir, 11(3)*:730-737 (1995).
	C65	Noda, Y. *et al.*, "Partitioning of Vasoactive Intestinal Polypeptide into Lipid Bilayers," *Biochimica et Biophysica Acta, 1191*:324-330 (1994).
	C66	Nucci, M.L. *et al.*, "The Therapeutic Value of Poly(ethylene glycol)-Modified Proteins," *Advanced Drug Delivery Reviews, 6*:133-151 (1991).
	C67	Ollerenshaw, S. *et al.*, "Absence of Immunoreactive Vasoactive Intestinal Polypeptide in Tissue from the Lungs of Patients with Asthma," *New England Journal of Medicine, 320*:1244-1248 (May, 1989).
	C68	Omary, M.B. *et al.*, "Identification of Nuclear Receptors for VIP on a Human Colonic Adenocarcinoma Cell Line," *Science, 238*:1578-1581 (1987)

EXAMINER	DATE CONSIDERED 5/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27611/36928	Serial No. 09/995,263
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Onyuksel, H. *et al.*	
		Filing Date November 27, 2001	Group 1615

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C69	Patel, M. *et al.*, "Simplified Preparation of Vasoactive Intestinal Peptide in Sterically Stabilized Liposomes," *Proceedings of International Controlled Release Bioactive Materials*, *24*:913-914 (1997).
	C70	Patel, M., "Study of Interactions Between Vasoactive Intestinal Peptide and Phospholipid Vesicles and Micelles," Masters Thesis, University of Illinois at Chicago, Chicago, Illinois (1997).
	C71	Paul, S. *et al.*, "Regulatory Aspects of the Vasoactive Intestinal Peptide Receptor in Lung," *Ann. N.Y. Acad. Sci., 527*:282-295 (1988).
	C72	Paul, S., "Vasoactive Intestinal Peptide: Its Interactions with Calmodulin and Catalytic Antibodies," *Neurochem. Int., 23(3)*:197-214 (1993).
	C73	Raud, J., "Intravital Microscopic Studies on Acute Mast Cell-Dependent Inflammation," *Acta Physiologica Scandinavica Supplementum 578*:1-58 (1989).
	C74	Robinson, R.M. *et al.*, "Lipid-Induced Conformational Changes in Glucagon, Secretin, and Vasoactive Intestinal Peptide," *Biopolymers, 21(6)*:1217-1228 (June 1982).
	C75	Rorstad, O.P. *et al.*, "Selectivity for Binding of Peptide Analogs to Vascular Receptors for Vasoactive Intestinal Peptide," *Molecular Pharmacology, 37*:971-977 (1990).
	C76	Rubinstein, *I. et al.*, "Tissue Angiotensin I-Converting Enzyme Activity in Spontaneously Hypertensive Hamsters," Biochemical and Biophysical Research Communications, *183(3)*:1117-1123 (March, 1992).
	C77	Rubinstein, I. *et al.*, "Cigarette Smoke Extract Attenuates Endothelium-Dependent Arteriolar Dilatation In Vivo," *Am. J. Physiol.*, 261 (*Heart Circ. Physiol.* 30):H1913-H1918 (1991).
	C78	Rubinstein, I., "L-Arginine Dilates Cheek Pouch Arterioles in Hamsters with Hereditary Cardiomyopathy but not in Controls," *J. Lab. Clin. Med.*, *125*:313-318 (1995).

EXAMINER	DATE CONSIDERED 5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27611/36928	Serial No. 09/995,263
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Onyuksel, H. *et al.*	
		Filing Date November 27, 2001	Group 1615

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C79	Said, S.I., "Vasoactive Intestinal Peptide (VIP) and Related Peptides as Anti-Asthma and Anti-Inflammatory Agents," *Biomedical Research, 13(Supplement 2)*:257-262 (1992).
	C80	Said, S.I., "Vasoactive Intestinal Polypeptide (VIP): Current Status," *Peptides, 5*:143-150 (1984).
	C81	Said, S.I., "Vasoactive Intestinal Polypeptide: Biological Role in health and Disease," *Trends Endocrinology Metab., 2(3)*:107-112 (1991).
	C82	Saletu, B. *et al.*, "Comparative Bioavailability Studies with a New Mixed-micelles Solution of Diazepam Utilizing Radioreceptor Assay, Psychometry and EEG Brain Mapping," *International Clinical Psychopharmacology, 3*:287-323 (1988).
	C83	Sansom, .S.P., "The Biophysics of Peptide Models of Ion Channels," *Prog. Biophys. Molec. Biol.,* 55:139-235 (1991).
	C84	Séjourné *et al.*, "Development of a Bioactive Formulation of Vasoactive Intestinal Peptide in Sterically Stabilized Liposomes," Pharm. Res., 13(Suppl. 9):S-95 (1996).
	C85	Séjourné, F. *et al.*, "Mechanisms of vasodilation elicited by VIP in sterically stabilized liposomes in vivo," *American Journal of Physiology, 273*:R287-R292 (1997).
	C86	Séjourné, F. *et al.*, "Development of a Novel Bioactive Formulation of Vasoactive Intestinal Peptide in Sterically Stabilized Liposomes," *Pharmaceutical Research, 14(3)*:362-365 (1997).
	C87	Shiraga, H. *et al.*, "Inhibition of calmodulin-dependent myosin light-chain kinase by growth-hormone-releasing factor and vasoactive intestinal peptide," *Biochem. J., 300*:901-905 (1994).
	C88	Smiley, J.D., "Southwestern Internal Medicine Conference: The Many Faces of Scleroderma," *American Journal Medical Sciences, 304*:319-333 (1992).

EXAMINER	DATE CONSIDERED 3/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27611/36928	Serial No. 09/995,263
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Onyuksel, H. *et al.*	
		Filing Date November 27, 2001	Group 1615

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C89	Soloviev, A.I., *et al.*, "Phospholipid Vesicles (Liposomes) Restore Endothelium-Dependent Cholinergic Relaxation in Thoracic Aorta from Spontaneously Hypertensive Rats," *J. Hypertension, 11*:623-627 (1993)
	C90	Sreedharan, S.P. *et al.*, "Human Vasoactive Intestinal Peptide Receptors Expressed By Stable Transfectants Couple To Two Distinct Signaling Pathways," *Biochemical Biophysical Research Communications, 203(1)*:141-148 (August, 1994).
	C91	Stallwood, D. *et al.*, "Identity of a Membrane-bound Vasoactive Intestinal Peptide-binding Protein with Calmodulin," *Journal of Biological Chemistry, 267(27)*:19617-19621 (September, 1992).
	C92	Suzuki, H. *et al.*, "Encapsulation of VIP into Liposomes Restores Vasorelaxation in Hypertension in Situ," *American Journal of Physiology, 271(Heart Circ. Physiol., 40)*:H282-H287 (1996).
	C93	Suzuki, H., *et al.*, "Encapsulation of Vasoactive Intestinal Peptide into Liposomes: Effects on Vasodilation *in Vivo*," *Life Sciences, 57(15)*:1451-1457 (1995).
	C94	Suzuki, H. *et al.*, "Neutral Endopeptidase Modulates VIP-Induced Vasodilation in Hamster Cheek Pouch Vessels In Situ," *Am. J. Physiol., 271(2 pt. 2)*:R393-397 (August, 1996).
	C95	Szucs, M., *et al.*, "Lyophilization and Rehydration of Polymer-coated Lipid Vesicles Containing a Lipophilic Chelator in the Presence of Sucrose: Labeling with ^{99m}Tc and Biodistribution Studies," *Nucl. Med. Biol., 22(2)*:263-268 (1995).
	C96	Theriault, Y. *et al.*, "Structural Determination of the Vasoactive Intestinal Peptide by Two-Dimensional H-NMR Spectroscopy," *Biopolymers, 31*:459-464 (1991).
	C97	Torchilin, V.P. *et al.* "Polymers on the Surface of Nanocarriers: Modulation of Carrier Properties and Biodistribution," *Polymer Science, 36(11)*:1585-1598 (1994).
	C98	Torchilin, V.P., "Polymer-coated long-circulating microparticulate pharmaceuticals," *J. Microencapsulation, 15(1)*:1-19 (1998).

EXAMINER	DATE CONSIDERED 5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27611/36928	Serial No. 09/995,263
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Onyuksel, H. *et al.*	
		Filing Date November 27, 2001	Group 1615

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C99	Trubetskoy, V. *et al.*, "Micellar Solubilization of Poorly Soluble or Amphiphilic Substances Using Polyoxyethylene-Lipid Conjugates," *Proceedings of International Symposium on Controlled Release Bioactive Materials, 22*:452-453 (1995).
	C100	Trubetskoy, V.S. *et al.*, "Stable Polymeric Micelles: Lymphangiographic Contrast Media for Gamma Scintigraphy and Magnetic Resonance Imaging," *Acad. Radiol., 3*:232-238 (1996).
	C101	Trubetskoy, V.S. *et al.*, "Polyethyleneglycol based micelles as carriers of therapeutic and diagnostic agents," *S.T.P. Pharma Sciences, 6(1)*:79-86 (1996).
	C102	Trubetskoy,V.S. *et al.*, "Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents," *Advanced Drug Delivery Reviews, 16*:311-320 (1995).
	C103	Watala, C., *et al.*, "Melittin-Induced Alterations in Dynamic Properties of Human Red Blood Cell Membranes," *Chem-Biol. Interactions, 82*:135-149 (1992).
	C104	Weissig, V. *et al.*, "A Micellar Delivery System For Dequalinium," *Proceed. Int'l. Symp. Control. Rel. Bioact. Mater., 25*:415-416 (1998).
	C105	Weissig, V. *et al.*, "Accumulation of Protein-Loaded Long-Circulating Micelles and Liposomes in Subcutaneous Lewis Lung Carcinoma in Mice," *Pharmaceutical Research, 15(10)*:1552-1556 (1998).
	C106	Weissig, V. *et al.*, "Micellar Delivery System For Dequalinium-A Lipophilic Cationic Drug With Anticarcinoma Activity," *Journal of Liposome Research, 8(3)*:391-400 (1998).
	C107	Woodle, M.C. *et al.*, "Improved Long Circulating (Stealth®) Liposomes Using Synthetic Lipids," *Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 17*:77-78 (1990).
	C108	Woodle, M.C. *et al.*, "Sterically stabilized liposomes," *Biochimica et Biophysica Acta, 113*:171-199 (1992).

EXAMINER	DATE CONSIDERED 5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27611/36928	Serial No. 09/995,263
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Onyuksel, H. *et al.*	
		Filing Date November 27, 2001	Group 1615

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
	C109	Woodle, M.C. *et al.*, "Versatility in Lipid Compositions Showing Prolonged Circulation with Sterically Stabilized Liposomes," *Biochimica et Biophysica Acta, 1105*:193-200 (1992).
	C112	Woodle, M.C. *et al.*," Prolonged Systemic Delivery of Peptide Drugs by Long-Circulating Liposomes: Illustration with Vasopressin in the Brattleboro Rat," *Pharmaceutical Research, 9(2)*:260-265 (1992).
	C111	Yokoyama, M. *et al.*, "Preparation of adriamycin-conjugated poly(ethylene glycol)-poly (aspartic acid) block copolymer," *Makromal Chem. Rapid Commun., 8*:431-435 (1987).
	C112	Zareie, H.M. *et al.*, "STM images of PDLLA-PEG copolymer micelles," *Colloids and Surfaces A: Physicochemical and Engineering Aspects, 112*:19-24 (1996).
	C113	Zia, H. *et al.*, "Breast Cancer Growth Is Inhibited by Vasoactive Intestinal Peptide (VIP) Hybrid, a Synthetic VIP Receptor Antagonist," *Cancer Research, 56*:3486-3489 (August, 1996).
	C114	Zorn, N.E. *et al.*, "Vasoactive Intestinal Peptide (VIP) Activation of Nuclear Protein Kinase C in Purified Nuclei of Rat Splenocytes," *Biochemical Pharmacology, 40*:2689-2694 (1990).

EXAMINER	DATE CONSIDERED 5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.